Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2026)
Top diagnostic & research stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Overview Zen Rating Price Value Growth Financials Momentum Sentiment

Diagnostics & Research is Zen Rated B and is the 34th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Shares	Institutional %	Insider %	Net Insider (L12M)	Net Insider (L3M)
ILMN	ILLUMINA INC	$17.99B	152,900,000	93.45%	6.55%	Net Buying	Net Buying
SHC	SOTERA HEALTH CO	$3.73B	284,392,079	86.78%	13.22%	Net Selling	Net Selling
IDXX	IDEXX LABORATORIES INC	$44.46B	79,624,034	98.26%	1.74%	Net Buying	Net Selling
BLLN	BILLIONTOONE INC	$3.20B	45,965,812	18.60%	25.95%	Net Buying
IQV	IQVIA HOLDINGS INC	$27.81B	169,700,000	53.65%	46.35%	Net Selling	Net Selling
MTD	METTLER TOLEDO INTERNATIONAL INC	$25.04B	20,325,250	95.44%	4.56%	Net Buying	Net Buying
NEOG	NEOGEN CORP	$1.89B	217,525,981	97.85%	2.15%	Net Buying	Net Buying
A	AGILENT TECHNOLOGIES INC	$31.15B	282,602,317	90.80%	1.27%	Net Buying	Net Buying
TMO	THERMO FISHER SCIENTIFIC INC	$175.85B	371,484,244	99.09%	0.91%	Net Buying	Net Selling
MEDP	MEDPACE HOLDINGS INC	$12.81B	28,381,283	26.66%	73.34%	Net Selling	Net Buying
RVTY	REVVITY INC	$9.38B	111,799,374	97.25%	2.75%	Net Selling	Net Selling
BNR	BURNING ROCK BIOTECH LTD	$171.40M	104,768,957	1.63%	17.75%
CAI	CARIS LIFE SCIENCES INC	$4.79B	282,579,919	40.00%	60.00%	Net Selling	Net Buying
DHR	DANAHER CORP	$128.36B	707,139,356	76.09%	23.91%	Net Selling	Net Selling
LH	LABCORP HOLDINGS INC	$21.77B	82,400,000	96.94%	1.55%	Net Selling	Net Selling
NTRA	NATERA INC	$25.89B	141,731,250	80.39%	19.61%	Net Selling	Net Selling
DGX	QUEST DIAGNOSTICS INC	$21.48B	109,866,320	96.61%	1.83%	Net Selling	Net Buying
PRPO	PRECIPIO INC	$45.50M	1,752,007	0.59%	99.41%	Net Buying	Net Buying
BDSX	BIODESIX INC	$140.09M	9,858,358	3.92%	96.08%	Net Buying	Net Buying
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$7.84B	49,227,800	96.61%	3.39%	Net Buying	Net Selling
MYGN	MYRIAD GENETICS INC	$400.21M	93,508,165	89.76%	10.24%	Net Selling	Net Selling
NEO	NEOGENOMICS INC	$933.35M	129,812,211	72.96%	27.04%	Net Buying	Net Selling
CDNA	CAREDX INC	$859.41M	51,216,344	77.00%	23.00%	Net Selling	Net Selling
WAT	WATERS CORP	$28.37B	98,101,871	58.81%	4.95%	Net Selling	Net Selling
QGEN	QIAGEN NV	$8.48B	216,920,735	69.19%	0.00%
CSTL	CASTLE BIOSCIENCES INC	$699.58M	29,731,198	86.02%	13.98%	Net Selling	Net Selling
ICLR	ICON PLC	$7.79B	76,359,932	99.47%	0.53%
LAB	STANDARD BIOTOOLS INC	$349.89M	390,071,506	49.23%	50.77%	Net Buying	Net Buying
TWST	TWIST BIOSCIENCE CORP	$2.73B	61,311,704	88.68%	11.32%	Net Selling	Net Selling
RDNT	RADNET INC	$4.36B	77,612,125	71.06%	28.94%	Net Selling	Net Selling
PSNL	PERSONALIS INC	$663.37M	104,631,832	68.86%	31.14%	Net Buying	Net Buying
GRAL	GRAIL INC	$1.89B	38,982,223	76.73%	21.39%	Net Selling	Net Buying
GH	GUARDANT HEALTH INC	$11.10B	131,170,441	68.90%	31.10%	Net Selling	Net Selling
PRE	PRENETICS GLOBAL LTD	$328.70M	16,034,309	10.85%	3.76%
MDXH	MDXHEALTH SA	$12.08M	49,497,334	43.94%	56.06%
OPK	OPKO HEALTH INC	$859.83M	767,701,280	20.62%	79.38%	Net Buying	Net Buying
ACRS	ACLARIS THERAPEUTICS INC	$381.38M	108,345,239	56.41%	43.59%	Net Selling	Net Selling
FLGT	FULGENT GENETICS INC	$486.89M	31,230,632	57.16%	41.96%	Net Selling	Net Selling
XGN	EXAGEN INC	$64.46M	24,053,058	44.97%	47.08%	Net Selling	Net Buying
STIM	NEURONETICS INC	$88.35M	68,485,922	56.27%	43.73%	Net Selling	Net Buying
IMDX	INSIGHT MOLECULAR DIAGNOSTICS INC	$114.52M	32,167,978	16.80%	83.20%	Net Buying	Net Buying
NDRA	ENDRA LIFE SCIENCES INC	$5.07M	1,166,441	5.33%	94.67%	Net Buying
FONR	FONAR CORP	$121.74M	6,555,521	39.45%	3.60%
QUCY	MAINZ BIOMED NV	$1.80M	4,091,853	28.15%	44.56%	Net Buying
MBAI	CHECK-CAP LTD	$249.22M	151,962,777	0.02%	0.00%
NOTV	INOTIV INC	$9.29M	34,394,971	22.01%	39.39%	Net Selling	Net Selling
ISPC	ISPECIMEN INC	$1.43M	9,771,028	1.30%	66.08%
SERA	SERA PROGNOSTICS INC	$72.42M	39,143,848	45.32%	25.38%	Net Selling	Net Selling
XWEL	XWELL INC	$6.92M	5,766,703	1.49%	98.51%
TRIB	TRINITY BIOTECH PLC	$11.08M	369,329,458	0.23%	0.00%
VNRX	VOLITIONRX LTD	$24.19M	122,801,572	13.15%	33.07%	Net Buying	Net Selling
DRIO	DARIOHEALTH CORP	$59.21M	7,300,406	5.02%	94.98%	Net Buying
BNBX	BNB PLUS CORP	$3.76M	5,447,469	2.37%	97.63%
ADVB	ADVANCED BIOMED INC	$4.53M	1,082,000	4.08%	0.00%
BIAF	BIOAFFINITY TECHNOLOGIES INC	$17.99M	4,498,675	1.60%	98.40%

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Mar 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Illumina (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) is the #1 top diagnostic & research stock out of 55 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Illumina (NASDAQ:ILMN) is: Value: B, Growth: C, Momentum: C, Sentiment: B, Safety: B, Financials: A, and AI: B.

Illumina (NASDAQ:ILMN) has a Due Diligence Score of 37, which is 9 points higher than the diagnostic & research industry average of 28.

ILMN passed 12 out of 33 due diligence checks and has average fundamentals. Illumina has seen its stock return 43.01% over the past year, overperforming other diagnostic & research stocks by 40 percentage points.

Illumina has an average 1 year price target of $138.60, an upside of 17.79% from Illumina's current stock price of $117.67.

Illumina stock has a consensus Buy recommendation according to Wall Street analysts. Of the 10 analysts covering Illumina, 30% have issued a Strong Buy rating, 10% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 10% have issued a Strong Sell.

2. Sotera Health Co (NASDAQ:SHC)

Sotera Health Co (NASDAQ:SHC) is the #2 top diagnostic & research stock out of 55 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Sotera Health Co (NASDAQ:SHC) is: Value: C, Growth: C, Momentum: C, Sentiment: B, Safety: B, Financials: B, and AI: C.

Sotera Health Co (NASDAQ:SHC) has a Due Diligence Score of 33, which is 5 points higher than the diagnostic & research industry average of 28.

SHC passed 11 out of 33 due diligence checks and has average fundamentals. Sotera Health Co has seen its stock return 11.27% over the past year, overperforming other diagnostic & research stocks by 8 percentage points.

Sotera Health Co has an average 1 year price target of $21.40, an upside of 62.99% from Sotera Health Co's current stock price of $13.13.

Sotera Health Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Sotera Health Co, 60% have issued a Strong Buy rating, 20% have issued a Buy, 20% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Idexx Laboratories (NASDAQ:IDXX)

Idexx Laboratories (NASDAQ:IDXX) is the #3 top diagnostic & research stock out of 55 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Idexx Laboratories (NASDAQ:IDXX) is: Value: C, Growth: C, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: B.

Idexx Laboratories (NASDAQ:IDXX) has a Due Diligence Score of 53, which is 25 points higher than the diagnostic & research industry average of 28.

IDXX passed 18 out of 33 due diligence checks and has strong fundamentals. Idexx Laboratories has seen its stock return 32.13% over the past year, overperforming other diagnostic & research stocks by 29 percentage points.

Idexx Laboratories has an average 1 year price target of $765.71, an upside of 37.15% from Idexx Laboratories's current stock price of $558.32.

Idexx Laboratories stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Idexx Laboratories, 71.43% have issued a Strong Buy rating, 0% have issued a Buy, 28.57% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.64%, which is 1 percentage points higher than the diagnostic & research industry average of 0.85%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 36.1% indicates that its dividend yield is sustainable for the long-term.

2. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 1.09%, which is the same as the diagnostic & research industry average of 0.85%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 27.3% indicates that its dividend yield is sustainable for the long-term.

3. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) has an annual dividend yield of 0.91%, which is the same as the diagnostic & research industry average of 0.85%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 22% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -3.3% in the last day, and down -0.87% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 100, which is 84 points higher than the diagnostic & research industry average of 16. It passed 7 out of 7 valuation due diligence checks.

Icon's stock has dropped -43.32% in the past year. It has underperformed other stocks in the diagnostic & research industry by -47 percentage points.

2. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 43, which is 27 points higher than the diagnostic & research industry average of 16. It passed 3 out of 7 valuation due diligence checks.

Qiagen Nv's stock has dropped -1.46% in the past year. It has underperformed other stocks in the diagnostic & research industry by -5 percentage points.

3. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Agilent Technologies has a valuation score of 14, which is -2 points higher than the diagnostic & research industry average of 16. It passed 1 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates A a Valuation Rating of "B".

Agilent Technologies's stock has dropped -7.34% in the past year. It has underperformed other stocks in the diagnostic & research industry by -11 percentage points.

Are diagnostic & research stocks a good buy now?

53.49% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 33.03% over the next year.

4.88% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 34.15% of diagnostic & research stocks are rated B (Buy), 46.34% are rated C (Hold), 14.63% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 20.17x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

Diagnostic & Research Stocks FAQ

1. Illumina (NASDAQ:ILMN)

2. Sotera Health Co (NASDAQ:SHC)

3. Idexx Laboratories (NASDAQ:IDXX)

1. Quest Diagnostics (NYSE:DGX)

2. Labcorp Holdings (NYSE:LH)

3. Agilent Technologies (NYSE:A)

1. Icon (NASDAQ:ICLR)

2. Qiagen Nv (NYSE:QGEN)

3. Agilent Technologies (NYSE:A)

Company

Stock Tools

Stock Ideas